SCHEMBL7712247

SCHEMBL7712247

COc1ccc(Cn2ccc3cccc(/C=C/C(=O)ON)c32)cc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PTGER3 P43115 7/20 0.61
▸ HDAC8 Q9BY41 7/20 0.49
▸ HDAC6 Q9UBN7 6/20 0.49
▸ HDAC3 O15379 5/20 0.49
▸ HDAC1 Q13547 5/20 0.49
▸ HDAC2 Q92769 5/20 0.49
▸ HDAC10 Q969S8 5/20 0.49
▸ HDAC11 Q96DB2 5/20 0.49
▸ HDAC4 P56524 4/20 0.49
▸ HDAC7 Q8WUI4 4/20 0.49
▸ HDAC9 Q9UKV0 4/20 0.49
▸ HDAC5 Q9UQL6 4/20 0.49
▸ APP P05067 3/20 0.43
▸ SNCA P37840 2/20 0.43
▸ PTGER4 P35408 1/20 0.43
▸ PTGER2 P43116 1/20 0.43
▸ MAOB P27338 1/20 0.43
▸ NCOR2 Q9Y618 1/20 0.41
▸ MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16130521 0.89 PTGER3 (0.49) PTGER3HDAC8HDAC6HDAC3HDAC1
SCHEMBL7712237 0.88 PTGER3 (0.56) PTGER3HDAC8HDAC6HDAC3HDAC1
SCHEMBL8358218 0.78 HDAC1 (0.46) PTGER3HDAC8HDAC6HDAC3HDAC1
SCHEMBL7712179 0.77 HDAC6 (0.62) HDAC8HDAC6HDAC3HDAC1HDAC2
SCHEMBL1271088 0.75 PTGER4 (0.54) PTGER3HDAC8HDAC6HDAC3HDAC1
SCHEMBL13238265 0.74 PTGER4 (0.47) PTGER3HDAC8HDAC6HDAC3HDAC1
SCHEMBL2884659 0.72 PTGER3 (0.62) PTGER3HDAC8HDAC6HDAC3HDAC1
SCHEMBL2884663 0.72 PTGER3 (0.62) PTGER3HDAC8HDAC6HDAC3HDAC1
SCHEMBL10019341 0.71 MAPT (0.47) PTGER3HDAC8HDAC6HDAC3HDAC1
SCHEMBL7706232 0.70 APP (0.56) HDAC8HDAC6HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9598364-B2 Indolyl or indolinyl hydroxamate compounds TAIPEI MEDICAL UNIVERSITY (TW) 2017-03-21 — — US disclosed
US-20140364477-A1 INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS TAIPEI MEDICAL UNIVERSITY (TW) 2014-12-11 — — US disclosed
US-8846748-B2 Indolyl or indolinyl hydroxamate compounds TAIPEI MEDICAL UNIVERSITY (TW) 2014-09-30 — — US disclosed
US-20110245315-A1 INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS TAIPEI MEDICAL UNIVERSITY (TW) 2011-10-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245315-A1 INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS IDH3A, IDH2, IDH3B PTGER3 1741/4885HDAC8 128/4885HDAC6 35/4885
US-20140364477-A1 INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS IDH3A, IDH2, IDH3B PTGER3 1741/4885HDAC8 128/4885HDAC6 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback